Ex vivo JAK and TNF inhibitor-modulated immune signatures guide first-line therapy selection in rheumatoid arthritis.
Overview & Synopsis
Open access biomedical research article published in Biomark Res.
Indexed from repository: PubMed Central
(
pmc.ncbi.nlm.nih.gov)
Keyboard Shortcuts:
← / → for pages • + / - for zoom • 0 to fit width
Powered by Mozilla PDF.js v3.11
Document Information
| Document Title | Ex vivo JAK and TNF inhibitor-modulated immune signatures guide first-line therapy selection in rheumatoid arthritis. |
|---|---|
| Author / Organization | Corrales S, Pérez-Sánchez C, Cerdó T, Merlo C, Malvar-Fernández B, García S, Muñoz-Barrera L, Sanchez-Pareja I, Formanti L, Moreno-Caño E, Ortega-Castro R, Calvo J, Aranda-Varela C, Ladehesa L, Font P, Abalos-Aguilera MC, Ruiz-Vilchez D, Aguirre MÁ, Barbarroja N, Alarcon-Riquelme ME, Escudero-Contreras A, López-Pedrera C |
| Subject & Discipline | Biomark Res |
| Categories | Medicine & Health |
| Publication Year | 2026 |
| License / Rights | Open Access / Creative Commons |
| Resource Verification | Listed PDF (Verification Pending) |
| Original Host Website |
PubMed Central
(pmc.ncbi.nlm.nih.gov)
|
| File Format | application/pdf (Portable Document Format) |
| Language | EN |
| Catalog ID | DOC-62519 |
| Original Source Link | Visit Source Page on pmc.ncbi.nlm.nih.gov » |